ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Antilymphocyte antibodies"

  • 2020 American Transplant Congress

    Outcomes of Acute Allograft Rejection Treatment with R Anti-Thymocyte Globulin (r-ATG) One Year Post Kidney Transplant

    M. Yaqub, A. Riaz, D. Mishler, O. Adebiyi, T. Taber, A. Sharfuddin

    Indiana University School of Medicine, Indianapolis, IN

    *Purpose: Acute allograft rejection is considered one of the major causes of renal allograft dysfunction. Despite maximal anti-rejection therapy grafts may not regain baseline function.…
  • 2020 American Transplant Congress

    Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture

    M. Colladant1, J. Lion2, P. Saas3, S. Perruche3, D. Ducloux1, N. Mooney2, J. Bamoulid1

    1Nephrologie, Dialyse et Transplantation, CHU de Besançon, Besancon, France, 2Equipe INSERM: Endothelium, Inflammation et Alloreactivity INSERM UMR-S 976, Paris, France, 3INSERM U1098 RIGHT, Université de Franche-Comté EFS Bourgogne Franche-Comté, Besancon, France

    *Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…
  • 2020 American Transplant Congress

    Carfilzomib-Based Desensitization: Effects on HLA, Non-HLA, Auto, and Antiviral Antibodies

    S. Tremblay1, E. Portwood1, A. R. Shields2, R. R. Alloway1, P. A. Brailey1, E. Woodle1

    1U Cincinnati, Cincinnati, OH, 2U Cincinnati, Christ Hospital, Cincinnati, OH

    *Purpose: An important question in plasma cell (PC) therapies is the specificity of therapy for PC populations. It is known that plasmablast populations are exquisitely…
  • 2020 American Transplant Congress

    Thymoglobulin Dose and Incidence of Biopsy Proven Acute Rejections in the Early Post Transplant Period

    K. Shimko, K. Schonder, D. Jorgensen, K. Kalra, A. Cherukuri, R. Mehta, I. Melgarejo, P. Sood, S. Hariharan, R. Mehta

    University of Pittsburgh Medical Center, Pittsburgh, PA

    *Purpose: Optimal dosing of thymoglobulin (ATG) for induction has not been well defined. Our protocol aims for 5-6mg/kg cumulative dose divided over 4 doses. However,…
  • 2020 American Transplant Congress

    Short Term Outcomes in Kidney Transplant Patients Receiving De Novo Belatacept with Anti-Thymocyte Globulin Induction

    B. Carlson, P. Cabrera, T. Harrison, K. Tejani, A. Centeno

    Pharmacy, Jackson Memorial Hospital, Miami, FL

    *Purpose: Mainstay immunosuppressive therapy after kidney transplant is a calcineurin inhibitor (CNI) based regimen. Nephrotoxicity is a common adverse effect of CNIs which can lead…
  • 2020 American Transplant Congress

    Outcomes of Induction with T Lymphocyte-Depleting and IL-2 Receptor Blocking (IL-2RB) Antibodies in the Non-Broadly Sensitized Adult Deceased-Donor Kidney Transplant Recipients: Analysis in the Context of the CPRA Allocation System

    A. H. Santos Jr1, Y. Li2, K. Alquadan1, M. Leghrouz1, X. Wen3

    1Div. of Nephrology, Univ. of Florida, Gainesville, FL, 2Univ. of Florida, Gainesville, FL, 3Univ. of Rhode Island, Kingston, RI

    *Purpose: We studied outcomes of induction in non-broadly-sensitized adult deceased-donor kidney transplant recipients(DD-KTRs) in the context of the calculated panel reactive antibody (CPRA) allocation system.*Methods:…
  • 2020 American Transplant Congress

    Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients in the Current Era of Immunosuppression

    M. Zachariah1, I. Mallawaarachchi2, N. Meeks3, D. Wright1, R. Minawala1, V. Liu1, J. Rolls4, S. Hussein4, C. Jarrin5

    1Wayne State University, Detroit, MI, 2Division of Biostatistics, University of Virginia, Charlottsville, VA, 3Wayne State University School of Medicine, Detroit, MI, 4Surgery, Detroit Medical Center, Detroit, MI, 5Infectious Disease, Wayne State University, Detroit, MI

    *Purpose: It is now common practice in the transplant community to select induction therapy on the basis of perceived immunological risk for acute rejection which…
  • 2020 American Transplant Congress

    Renal Transplant Induction Therapy Safety Outcomes Comparison

    R. M. Hofmann1, J. Combs2, K. J. Schmidt3, T. Dyckman4

    1Nephrology, Renal Associates of West Michigan, Grand Rapids, MI, 2Pharmacy/Transplant, Mercy Health St. Mary's, Grand Rapids, MI, 3Pharmacy, Ferris State University College of Pharmacy, Big Rapids, MI, 4Pharmacy, Mercy Health St. Mary's, Grand Rapids, MI

    *Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…
  • 2020 American Transplant Congress

    Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients

    K. Soliman1, H. Ali2, T. Fulop1, A. Osman3, A. Halawa4

    1Medicine, Medical University of South Carolina, Charleston, SC, 2Medicine, Royal Stoke, Royal Stoke, United Kingdom, 3Medicine, Cairo University, Cairo, Egypt, 4Medicine, University of Liverpool, Liverpool, United Kingdom

    *Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…
  • 2019 American Transplant Congress

    Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model

    J. Lei1, H. Deng1, K. Lee1, C. Peters1, G. Rickert1, R. Ivy1, M. Coronel2, E. Yolcu3, H. Shirwan4, A. García5, J. Markmann1

    1Surgery, Massachusetts General Hospital, Boston, MA, 2Surgery, Georgia Institute of Technology, Atlanta, GA, 3Institute for Cellular Therapeutics, University of Louisville School of Medicine, louisville, KY, 4Department of Microbiology and Immunology, University of Louisville School of Medicine, louisville, KY, 5School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA

    *Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences